MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

62.36
-0.04
-0.06%
After Hours: 62.36 0 0.00% 16:42 09/21 EDT
OPEN
62.61
PREV CLOSE
62.40
HIGH
63.94
LOW
62.13
VOLUME
326.96K
TURNOVER
--
52 WEEK HIGH
93.66
52 WEEK LOW
41.26
MARKET CAP
6.50B
P/E (TTM)
-51.0854
1D
5D
1M
3M
1Y
5Y
Insider Sell: Arrowhead Pharmaceuticals
MT Newswires · 09/14 17:38
Despite shrinking by US$371m in the past week, Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders are still up 804% over 5 years
It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders, since the share price...
Simply Wall St. · 09/13 12:11
IronBridge Private Wealth, LLC Buys iShares Core S&P 500 ETF, Materials Select Sector SPDR, ...
GuruFocus News · 09/01 22:38
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
PASADENA, Calif., September 01, 2021--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Business Wire · 09/01 11:30
Is Arrowhead Pharmaceuticals (ARWR) A Good Stock To Buy Now?
Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here. During the second quarter of 2021, the Baron Opportunity Fund returned 10.14% (institutional shares). In comparison, the benchmark S&P 500 Ind...
Insider Monkey · 08/27 05:51
ARWR: New Program Targeting Complement C3 Highlights Expanding Pipeline…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT
Benzinga · 08/10 15:20
HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $100
HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $95 to $100.
Benzinga · 08/10 10:02
--HC Wainwright Adjusts Arrowhead Pharmaceuticals' Price Target to $100 From $95, Keeps Buy Rating
MT Newswires · 08/10 07:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARWR. Analyze the recent business situations of Arrowhead Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARWR stock price target is 87.92 with a high estimate of 106.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 442
Institutional Holdings: 77.70M
% Owned: 74.52%
Shares Outstanding: 104.26M
TypeInstitutionsShares
Increased
97
1.96M
New
51
1.07M
Decreased
108
3.88M
Sold Out
26
710.24K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Senior Vice President
James Hamilton
Chief Scientific Officer
Curt Bradshaw
Chief Compliance Officer/General Counsel/Secretary
Patrick O'Brien
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Oye Olukotun
Independent Director
William Waddill
No Data
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.